EXAS
Price
$53.81
Change
+$2.40 (+4.67%)
Updated
Sep 5 closing price
Capitalization
10.19B
53 days until earnings call
SARTF
Price
$187.87
Change
-$2.13 (-1.12%)
Updated
Aug 22 closing price
Capitalization
13.87B
Interact to see
Advertisement

EXAS vs SARTF

Header iconEXAS vs SARTF Comparison
Open Charts EXAS vs SARTFBanner chart's image
Exact Sciences
Price$53.81
Change+$2.40 (+4.67%)
Volume$4.19M
Capitalization10.19B
Sartorius AG
Price$187.87
Change-$2.13 (-1.12%)
Volume$1
Capitalization13.87B
EXAS vs SARTF Comparison Chart in %
Loading...
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SARTF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXAS vs. SARTF commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXAS is a StrongBuy and SARTF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (EXAS: $53.81 vs. SARTF: $187.87)
Brand notoriety: EXAS: Notable vs. SARTF: Not notable
EXAS represents the Medical Specialties, while SARTF is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EXAS: 131% vs. SARTF: 8%
Market capitalization -- EXAS: $10.19B vs. SARTF: $13.87B
EXAS [@Medical Specialties] is valued at $10.19B. SARTF’s [@Pharmaceuticals: Other] market capitalization is $13.87B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $162.93B to $0. The average market capitalization across the [@Medical Specialties] industry is $10.68B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $11.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXAS’s FA Score shows that 0 FA rating(s) are green whileSARTF’s FA Score has 0 green FA rating(s).

  • EXAS’s FA Score: 0 green, 5 red.
  • SARTF’s FA Score: 0 green, 5 red.
According to our system of comparison, EXAS is a better buy in the long-term than SARTF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXAS’s TA Score shows that 4 TA indicator(s) are bullish while SARTF’s TA Score has 3 bullish TA indicator(s).

  • EXAS’s TA Score: 4 bullish, 5 bearish.
  • SARTF’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, SARTF is a better buy in the short-term than EXAS.

Price Growth

EXAS (@Medical Specialties) experienced а +13.48% price change this week, while SARTF (@Pharmaceuticals: Other) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.01%. For the same industry, the average monthly price growth was +8.25%, and the average quarterly price growth was +13.64%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.24%. For the same industry, the average monthly price growth was +7.04%, and the average quarterly price growth was +16.54%.

Reported Earning Dates

EXAS is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Medical Specialties (+1.01% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

@Pharmaceuticals: Other (-1.24% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SARTF($13.9B) has a higher market cap than EXAS($10.2B). SARTF YTD gains are higher at: 2.103 vs. EXAS (-4.236). SARTF has higher annual earnings (EBITDA): 844M vs. EXAS (-758.48M). SARTF (872M) and EXAS (858M) have equal amount of cash in the bank . EXAS has less debt than SARTF: EXAS (2.52B) vs SARTF (4.66B). SARTF has higher revenues than EXAS: SARTF (3.47B) vs EXAS (2.94B).
EXASSARTFEXAS / SARTF
Capitalization10.2B13.9B73%
EBITDA-758.48M844M-90%
Gain YTD-4.2362.103-201%
P/E RatioN/A107.42-
Revenue2.94B3.47B85%
Total Cash858M872M98%
Total Debt2.52B4.66B54%
FUNDAMENTALS RATINGS
EXAS vs SARTF: Fundamental Ratings
EXAS
SARTF
OUTLOOK RATING
1..100
1427
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9687
PRICE GROWTH RATING
1..100
5560
P/E GROWTH RATING
1..100
10089
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXAS's Valuation (39) in the Biotechnology industry is somewhat better than the same rating for SARTF (76) in the null industry. This means that EXAS’s stock grew somewhat faster than SARTF’s over the last 12 months.

EXAS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SARTF (100) in the null industry. This means that EXAS’s stock grew similarly to SARTF’s over the last 12 months.

SARTF's SMR Rating (87) in the null industry is in the same range as EXAS (96) in the Biotechnology industry. This means that SARTF’s stock grew similarly to EXAS’s over the last 12 months.

EXAS's Price Growth Rating (55) in the Biotechnology industry is in the same range as SARTF (60) in the null industry. This means that EXAS’s stock grew similarly to SARTF’s over the last 12 months.

SARTF's P/E Growth Rating (89) in the null industry is in the same range as EXAS (100) in the Biotechnology industry. This means that SARTF’s stock grew similarly to EXAS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXASSARTF
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
58%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
64%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
64%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
51%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
55%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
55%
Advances
ODDS (%)
Bullish Trend 1 day ago
71%
N/A
Declines
ODDS (%)
Bearish Trend 26 days ago
81%
N/A
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
61%
Aroon
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SARTF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EIM10.230.43
+4.39%
Eaton Vance Municipal
FBL45.860.40
+0.88%
GraniteShares 2x Long META Daily ETF
SPTS29.300.05
+0.17%
SPDR® Portfolio Short Term Treasury ETF
GK25.230.03
+0.14%
AdvisorShares Gerber Kawasaki ETF
ZMAR26.90-0.01
-0.03%
Innovator Equity Defined Prt ETF -1YrMar

SARTF and

Correlation & Price change

A.I.dvisor tells us that SARTF and SOAGY have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SARTF and SOAGY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SARTF
1D Price
Change %
SARTF100%
N/A
SOAGY - SARTF
25%
Poorly correlated
+3.02%
RVTY - SARTF
25%
Poorly correlated
+1.10%
SRTOY - SARTF
24%
Poorly correlated
N/A
EXAS - SARTF
24%
Poorly correlated
+4.67%
WAT - SARTF
21%
Poorly correlated
+2.21%
More